Chandrikha Chandrasekharan, MD
Medical Oncology · Houston, TXNPI 1780814491
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Exelixis Inc. at 52.8% of the total.
Across 31 payments — averaging $516.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$8K
- Lexicon Pharmaceuticals, Inc.$4K
- Ipsen Biopharmaceuticals, Inc$2K
- Curium US LLC$2K
- Daiichi Sankyo Inc.$164
- Array Biopharma Inc$139
- plus $137 from 4 others
Across 66 payments — averaging $16,956 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$645K
- Merck$217K
- Boston Scientific$94K
- Seagen Inc.$92K
- Genentech, Inc.$40K
- Novartis$32K
What the payments were for
- Consulting fees$4,76030%
- Speaking & faculty fees$7,34546%
- Travel & lodging$2,65017%
- Food & beverage$1,0957%
- Education$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 13 | $8,460 |
| Lexicon Pharmaceuticals, Inc. | 4 | $3,897 |
| Ipsen Biopharmaceuticals, Inc | 2 | $1,639 |
| Curium US LLC | 5 | $1,578 |
| Daiichi Sankyo Inc. | 2 | $164 |
| Array Biopharma Inc | 1 | $139 |
| Novartis | 1 | $90 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Viiv Healthcare Company | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$8,175
- Xermelo$3,897
- SOMATULINE DEPOT$1,500
- TAZVERIK$139
How this compares
$16,014 in reported general payments places this provider in the 65th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 31 | $42,946 |
| EliquisApixaban | 18 | $10,542 |
| Octreotide Acetate | 15 | $5,398 |
| Ondansetron Hcl | 65 | $746 |
| Prochlorperazine Maleate | 56 | $651 |
| Dexamethasone | 139 | $425 |
| Oxycodone Hcl | 25 | $320 |
| Famotidine | 18 | $197 |
| Omeprazole | 12 | $109 |
| Hydromorphone Hcl | 12 | $86 |
| Levothyroxine Sodium | 11 | $34 |
| Prednisone | 17 | $29 |
| Lorazepam | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.